Anders Lyngaa Kristoffersen (Novozymes) to be a panellist in the “Investments in industrial biotech” session
Financing session panelist Anders Lyngaa Kristoffersen, Public Affairs Manager at Novozymes
Capital requirements for the realization of IB projects are substantial, especially when it comes to commercial scale production. European public support schemes are rarely directed towards demonstration activities, so the investment climate in the EU is rather risk-averse and does not foster the development of the IB sector. Anders Kristoffersen from Novozymes explains:
“In comparison to the US where the USDA delivers loan guarantees and Brazil where the construction of advanced biorefineries is supported by the BNDES, Europe does not seem very attractive in terms of financing. The only commercial scale advanced biorefinery in Europe was mainly financed by private partners, with only some support from the Commission and the national level. “
While the Biobased Industries Public Private Partnership is a step in the right direction, it can only finance a relatively small part of the project. Anders Kristoffersen envisages pension funds focusing on green technologies playing a larger role in the IB sphere in the future.
Anders Kristoffersen: “Positive framework conditions for IB which drive demand need to be put in place in order to ensure that the products, jobs and growth it generates can benefit the European citizen. Such measures build-up investor confidence and have the power to unlock the next wave of biorefineries, those that come after the flagships.”
Do not miss the launch of the BIO-TIC action plan for overcoming hurdles to industrial biotechnology in Europe and driving a smart and sustainable (bio)economy in Europe. Join the final policy-maker conference entitled “From bugs to business: Unlocking the Bioeconomy in Europe” on 23rd June 2015 at KVAB (Flemish Academy for Science and the Arts), Brussels. Register now at www.bio-tic-conference.eu . Follow the conference news on twitter via #bioeconomy4EU.
Novozymes is a biotech company with a strong focus on enzyme production. We are committed to changing the very foundations of our industrial system for the better by using industrial biotechnology. As the world leader in bioinnovation we believe that by using industrial biotechnology we can potentially re-engineer thousands of everyday products to deliver enhanced sustainability performance, introducing energy cost savings, and decreased raw material costs for our customers.
We market more than 700 biotechnology products across in 130 countries. Our never-ending exploration of nature’s potential is evidenced by over 6,000 patents – an indication of what is possible when nature and technology join forces in biotechnology, and we are continuously and proactively seeking partners to license or inlicense patents within our interest areas. Our 6,200+ employees working in research, production, and sales around the world are committed to shaping the businesses of today and the world of tomorrow. The enzyme production leaves Novozymes with a global enzyme market share of 48% (estimated).
For more information, please visit: www.novozymes.com
Anders Lyngaa Kristoffersen (Denmark) is leading Novozymes’ Public Affairs activities related to Bioenergy globally. A large part of this work relates to financing as this area plays a key role in deploying biofuels (in particular advanced biofuels). In addition to leading Novozymes’ global public affairs activities related to bioenergy, Anders is charge of driving Novozymes’ Public Affairs in Denmark. Anders Kristoffersen has been working for Novozymes since November 2008.
Before joining Novozymes Anders worked at the World Bank in Washington DC and as a management consultant for two leading consulting companies (Accenture and Dalberg Global Development Advisors). He also advised the Danish Government on environmental matters.
Anders holds a master of science in engineering from Technical University of Denmark.